# Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

> **NCT00147537** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 282 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** CP-751,871
- **DRUG:** paclitaxel
- **DRUG:** carboplatin
- **DRUG:** CP-751,871
- **DRUG:** paclitaxel
- **DRUG:** carboplatin
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00147537
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2013-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00147537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00147537, "Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00147537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*